/
/
Myeloma Crowd Launches a Psoriasis / Multiple Myeloma Study Using Its HealthTree® Platform
Myeloma Crowd Launches a Psoriasis / Multiple Myeloma Study Using Its HealthTree® Platform image
Myeloma Crowd Launches a Psoriasis / Multiple Myeloma Study Using Its HealthTree® Platform
Posted Oct 02, 2019

As seen on PRNewswire

HealthTree IRB-Approved Data Study to Identify Potential Correlations Between Diseases

SALT LAKE CITY, Oct. 2, 2019 /PRNewswire/ -- The Myeloma Crowd™, a division of the CrowdCare Foundation, today announced the launch of a new study to identify correlations between psoriasis and multiple myeloma. Psoriasis is an auto-immune disease of the skin and multiple myeloma is a rare blood cancer in which the cancer has escaped the immune system.

Participants will join the study via the HealthTree® platform, a new online tool that helps multiple myeloma patients find their best myeloma treatments and accelerate research toward a cure. There are currently more than 4,500 myeloma patients registered in HealthTree.

"This study demonstrates the importance of HealthTree as a tool for patients to connect with opportunities that could help them directly and accelerate a cure," said Myeloma Crowd founder and myeloma patient Jenny Ahlstrom. "HealthTree has been designed as a model for curing disease by leveraging the crowd, starting with myeloma with the intent of expanding to other cancers and beyond."

Research shows that multiple myeloma growth and bone damage can occur through activity of the interleukin-17 pathway. IL-17 is also a known treatment target in psoriasis, with several anti-IL-17 monoclonal antibodies currently FDA-approved as psoriasis therapy.  Other joint cytokines and targets may be applicable.

Dana Farber Cancer Institute researchers performed initial work assessing the utility of anti-IL-17 psoriasis mediations to treat multiple myeloma in mouse models. Further research is needed to identify possible connections between the two diseases.

The Myeloma Crowd invites all multiple myeloma patients with psoriasis to join this important study by registering in HealthTree and adding their psoriasis diagnosis to their full health profile.

HealthTree was developed by Myeloma Crowd founders Jenny Ahlstrom, who is also a former Systems Engineer for IBM, and her husband Paul Ahlstrom, an investor and entrepreneur. HealthTree is free for myeloma patients.

To join the psoriasis/myeloma study, create a patient profile on www.healthtree.org. Please note if you have psoriasis in the Full Health Profile and choose to join study by clicking the Accelerate Myeloma Research tile and selecting Yes on the Psoriasis survey question.

About Myeloma Crowd/CrowdCare Foundation

The Myeloma Crowd is a division of the CrowdCare Foundation, a patient-driven 501(c)3 non-profit organization. The Myeloma Crowd provides patient education, advocacy and research funding for multiple myeloma. www.myelomacrowd.org.

SOURCE Myeloma Crowd: CrowdCare Foundation

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811